Patents by Inventor Limin Xiong

Limin Xiong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods comprising binding proteins for adalimumab
    Patent number: 9321846
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: April 26, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB
    Publication number: 20150166678
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Compositions and methods comprising binding proteins for adalimumab
    Patent number: 8969024
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 3, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Compositions and methods comprising binding proteins for adalimumab
    Publication number: 20090068172
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Application
    Filed: August 27, 2008
    Publication date: March 12, 2009
    Inventors: Zehra Kaymakcalan, Limin Xiong